Patients' Reasons for Adhering to Long-term Alendronate Therapy

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2019 May 16

PMID 31089764

Citations 7

Authors

J Pepe

C Cipriani

V Cecchetti

C Ferrara

G Della Grotta

V Danese

L Colangelo

S Minisola

Affiliations

Soon will be listed here.

Abstract

Introduction: Aim of this study was to investigate patients' reasons for adhering to long-term alendronate therapy (more than 5 years), as data is not available in the current literature regarding the reasons behind long-term adherence.

Methods: We studied 204 long-term adherent alendronate users: 65 postmenopausal outpatients still adherent (group C, years on treatment = 8.70 ± 1.31) were compared to 139 age-matched patients who discontinued therapy (group S, years on treatment = 8.64 ± 1.43). We evaluated main biochemical parameters, BMD values, fractures, and Charlson comorbidity index (CCI). A questionnaire was administered to analyze the reasons for long-term adherence.

Results: There were no significant differences between groups concerning baseline DXA values, number of fractures, and CCI. A higher education level was observed in group C (C 54% vs S 35% of patients, p = 0.001). At the time of interview, there was a significantly higher number of patients with a CCI of two in group S compared to the beginning of treatment (56% vs 43%, p = 0.04), together with a higher number of patients taking more than 3 drugs (22% vs 11%, p = 0.01) compared to basal evaluation. Forty-seven percent of patients reported new diseases during the treatment as the main reason for stopping alendronate. A multivariate, stepwise logistic regression analysis showed that awareness of the disease was highly associated with adherence (OR = 0.20; 95% CI 0.045-0.93, p = 0.04) followed by higher education (OR = 0.526, 95% CI 0.345-0.801, p = 0.003). Worsening of CCI was associated with discontinuation (OR = 2.75, 95% CI 1.033-7.324, p = 0.04).

Conclusions: Education and disease awareness are associated with long-term alendronate adherence while competing health problems negatively impact adherence.

Citing Articles

Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study.

Leung M, Turner J, Marquina C, Ilomaki J, Tran T, Bell J Osteoporos Int. 2024; 35(4):669-678.

PMID: 38195713 PMC: 10957648. DOI: 10.1007/s00198-023-06974-6.

Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021.

Corrao G, Biffi A, Porcu G, Ronco R, Adami G, Alvaro R Front Endocrinol (Lausanne). 2023; 14:1137671.

PMID: 37143730 PMC: 10151776. DOI: 10.3389/fendo.2023.1137671.

Hyperin up-regulates miR-7031-5P to promote osteogenic differentiation of MC3T3-E1 cells.

Qian D, Chen Y, Qiu X, Zhu B, Zhang L, Yan Y Histol Histopathol. 2023; 38(10):1219-1229.

PMID: 36633331 DOI: 10.14670/HH-18-579.

Socio-economic inequalities in the use of drugs for the treatment of chronic diseases in Italy.

Di Filippo A, Perna S, Pierantozzi A, Milozzi F, Fortinguerra F, Caranci N Int J Equity Health. 2022; 21(1):157.

PMID: 36352409 PMC: 9644599. DOI: 10.1186/s12939-022-01772-8.

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up.

Martino G, Bellone F, Vicario C, Gaudio A, Caputo A, Corica F Int J Environ Res Public Health. 2021; 18(15).

PMID: 34360437 PMC: 8346074. DOI: 10.3390/ijerph18158144.

References

Klop C, Welsing P, Elders P, Overbeek J, Souverein P, Burden A . Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int. 2015; 26(6):1831-40. PMC: 4469296. DOI: 10.1007/s00198-015-3084-3. View

Yeam C, Chia S, Tan H, Kwan Y, Fong W, Seng J . A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018; 29(12):2623-2637. DOI: 10.1007/s00198-018-4759-3. View

Paglia F, Dionisi S, De Geronimo S, Rosso R, Romagnoli E, Raejntroph N . Biomarkers of bone turnover after a short period of steroid therapy in elderly men. Clin Chem. 2001; 47(7):1314-6. View

Wysowski D, Greene P . Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013; 57(2):423-8. DOI: 10.1016/j.bone.2013.09.008. View

van den Berg P, van Haard P, van der Veer E, Geusens P, van den Bergh J, Schweitzer D . A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates. Osteoporos Int. 2017; 29(4):813-824. DOI: 10.1007/s00198-017-4340-5. View

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate J . Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2009; 21(11):1943-51. DOI: 10.1007/s00198-009-1134-4. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Hansen C, Pedersen B, Konradsen H, Abrahamsen B . Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int. 2012; 24(7):2079-97. DOI: 10.1007/s00198-012-2221-5. View

Pepe J, Isidori A, Falciano M, Iaiani G, Salotti A, Diacinti D . Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study. Endocrine. 2014; 47(2):456-62. DOI: 10.1007/s12020-014-0349-0. View

10.

Montomoli M, Gonnelli S, Giacchi M, Mattei R, Cuda C, Rossi S . Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italian women. Eur J Clin Nutr. 2002; 56(1):21-30. DOI: 10.1038/sj.ejcn.1601278. View

11.

Belhassen M, Confavreux C, Cortet B, Lamezec L, Ginoux M, Van Ganse E . Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int. 2016; 28(3):853-862. DOI: 10.1007/s00198-016-3789-y. View

12.

Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert R . Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82(12):1493-501. DOI: 10.1016/S0025-6196(11)61093-8. View

13.

Nuti R, Brandi M, Checchia G, Di Munno O, Dominguez L, Falaschi P . Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2018; 14(1):85-102. PMC: 6329834. DOI: 10.1007/s11739-018-1874-2. View

14.

Ganda K, Schaffer A, Pearson S, Seibel M . Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int. 2014; 25(4):1345-55. DOI: 10.1007/s00198-013-2610-4. View

15.

Wu X, Wei D, Sun B, Wu X . Poor medication adherence to bisphosphonates and high self-perception of aging in elderly female patients with osteoporosis. Osteoporos Int. 2016; 27(10):3083-90. DOI: 10.1007/s00198-016-3763-8. View

16.

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O . Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015; 26(10):2401-11. PMC: 4575381. DOI: 10.1007/s00198-015-3253-4. View

17.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

18.

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View

19.

Diacinti D, Del Fiacco R, Pisani D, Todde F, Cattaruzza M, Diacinti D . Diagnostic performance of vertebral fracture assessment by the lunar iDXA scanner compared to conventional radiography. Calcif Tissue Int. 2012; 91(5):335-42. DOI: 10.1007/s00223-012-9643-0. View

20.

Lo J, Pressman A, Omar M, Ettinger B . Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8. DOI: 10.1007/s00198-006-0085-2. View